Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CE-VST 01 JC

Next Previous
X
Search
Drug Profile

CE-VST 01 JC

Alternative Names: CE-VST-01-JC; JCPyV-specific T cell therapy - Cellevolve

Latest Information Update: 16 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellevolve
  • Class Gene therapies; Neuroprotectants; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive multifocal leukoencephalopathy
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Progressive multifocal leukoencephalopathy

Most Recent Events

  • 22 Apr 2023 Pharmacodynamics data from a preclinical trial in Progressive multifocal leukoencephalopathy presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
  • 08 Dec 2022 Phase-I/II clinical trials in Progressive multifocal leukoencephalopathy in USA (IV) prior to December 2022 (Cellevolve pipeline, December 2022)
  • 25 Oct 2022 CE-VST 01 JC receives Orphan Drug status for Progressive multifocal leukoencephalopathy in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top